Clinical Trial Update: Microbiome of Depression & Treatment Response to Citalopram

View source ↗

Summary

A completed Mayo Clinic trial studying how the microbiome relates to depression and response to citalopram treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Bipolar Ii Disorder
• Major Depressive Disorder

Drugs mentioned

• Citalopram (Citalopram hydrobromide)

Snippet

Sponsor: Mayo Clinic | Conditions: Major Depressive Disorder, Bipolar I and Bipolar II | Status: COMPLETED